Official Title
Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19
Brief Summary

This prospective randomized single Center study investigates to what extent the physical elimination of the inflammatory mediators using the CytoSorb adsorber reduces the morbidity of severely and critically ill patients with Covid-19.

Recruiting
COVID-19

Device: CytoSorb-Therapy
Additional use of Cytosorb-Adsorber in patients with COVID-19 and need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation)
CytoSorb-Therapy

Eligibility Criteria

Inclusion Criteria:

- confirmed COVID-19 disease

- refractory shock with need for norepinephrine ≥ 0.2 μg/kg/min for MAP ≥ 65 mmHg

- IL6 ≥ 500 ng/l

- Indication for CRRT or ECMO

Exclusion Criteria:

- Liver cirrhosis Child Pugh C

- "do not resuscitate"-order

- expected survival due to comorbidities < 14 days

- pregnancy or breastfeeding

- participation in another interventional trial

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years~Maximum: 90 Years
Countries
Germany
Contacts

Dominik Jarczak, MD
+49 40 741035315
d.jarczak@uke.de

Axel Nierhaus, MD
+49 40 741035315
nierhaus@uke.de

Stefan Kluge, MD
Principal Investigator
University Hospital Hamburg-Eppendorf, Department of Intensive Care Medicine

Universitätsklinikum Hamburg-Eppendorf
NCT Number
Keywords
Critically Ill
intensive care medicine
CytoSorb
hemoadsorption